References
- AutierPBoniolMLa VecchiaCDisparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality databaseBMJ2010341c362020702548
- BerryDACroninKAPlevritisSKEffect of screening and adjuvant therapy on mortality from breast cancerN Engl J Med2005353171784179216251534
- EdgeSBAdvances in breast surgery, 2002–2012J Natl Compr Canc Netw2013111535923307981
- CortazarPZhangLUntchMPathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisLancet2014384993816417224529560
- OvermoyerBOptions for the treatment of patients with taxane-refractory metastatic breast cancerClin Breast Cancer20088Suppl 2S61S7018637401
- DesaiNTrieuVYaoZIncreased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxelClin Cancer Res20061241317132416489089
- GradisharWJTjulandinSDavidsonNPhase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancerJ Clin Oncol200523317794780316172456
- GradisharWJKrasnojonDCheporovSSignificantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancerJ Clin Oncol200927223611361919470941
- DowsettMProcterMMcCaskill-StevensWDisease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA TrialJ Clin Oncol200927182962296919364966
- HuangLChenTChenCPrognostic and predictive value of Phospho-p44/42 and pAKT in HER2-positive locally advanced breast cancer patients treated with anthracycline-based neoadjuvant chemotherapyWorld J Surg Oncol20131130724289519
- EarlHMVallierALHillerLEffects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2x2 factorial randomised phase 3 trialLancet Oncol201415220121224360787
- YuKDLiuGYChenCMWeekly paclitaxel/carboplatin/trastuzumab therapy improves pathologic complete remission in aggressive HER2-positive breast cancers, especially in luminal-B subtype, compared with a once-every-3-weeks scheduleOncologist201318551151723635560
- GianniLPienkowskiTImYHEfficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialLancet Oncol2012131253222153890
- RobertNLeyland-JonesBAsmarLRandomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancerJ Clin Oncol200624182786279216782917
- BurrisH3rdYardleyDJonesSPhase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancerJ Clin Oncol20042291621162915117984
- BullockKBlackwellKClinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancerOncologist200813551552518515736
- SlamonDEiermannWRobertNAdjuvant trastuzumab in HER2-positive breast cancerN Engl J Med2011365141273128321991949
- YardleyDARaefskyECastilloRPhase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancerClin Breast Cancer201111529730521729666
- ChengHBaiYSikovWQuantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumabBMC Cancer20141432624885187
- MrozekELaymanRRamaswamyBPhase II trial of neoadjuvant weekly nanoparticle albumin-bound paclitaxel, carboplatin, and biweekly bevacizumab therapy in women with clinical stage II or III HER2-negative breast cancerClin Breast Cancer201414422823424703985
- SonkeGSMandjesIAHoltkampMJPaclitaxel, carboplatin, and trastuzumab in a neo-adjuvant regimen for HER2-positive breast cancerBreast J201319441942623682812
- ChenXSNieXQChenCMWeekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancerAnn Oncol201021596196720211870